- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2025 | 719 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2025ISIN NameCA74349R1055 PROPHECY... ► Artikel lesen | |
| 11.12.25 | NGM MARKET NOTICE: #25-119 Decision on delisting of Diagonal Bio AB from Nordic SME | 5 | Cision News | ||
| 11.12.25 | XFRA 9F1: AUSSETZUNG/SUSPENSION | 277 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDIAGONAL BIO AB... ► Artikel lesen | |
| 11.12.25 | NGM MARKET NOTICE: #25-118 Trading halt in Diagonal Bio AB | 6 | Cision News | ||
| 04.03.25 | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 373 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03.25 | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 294 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 12,505 | -5,44 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,418 | +2,03 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ATAIBECKLEY | 3,120 | -3,70 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 25.02.2026 | Das Instrument B72 US04650F1012 ATAIBECKLEY INC. O.N. EQUITY hat seinen ersten Handelstag am 25.02.2026: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y
The instrument B72 US04650F1012... ► Artikel lesen | |
| BIOMERIEUX | 99,20 | -1,88 % | BioMerieux SA Profit Declines In Full Year | PARIS (dpa-AFX) - BioMerieux SA (EYWN.MU) reported earnings for full year that Drops, from the same period last yearThe company's bottom line totaled EUR397.5 million, or EUR3.34 per share.... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 1,020 | 0,00 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 33,000 | +0,61 % | Genus PLC - Director/PDMR Shareholding | ||
| ANAPTYSBIO | 47,000 | 0,00 % | AnaptysBio, Inc.: Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology... ► Artikel lesen | |
| ABIONYX PHARMA | 3,280 | -0,46 % | ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2025 | Consolidated revenue of €4.1 million at the end of December 2025 Cash position of €3.5 million as of December 31, 2025 Cash runway through year-end 2026 excluding France 2030 non-dilutive... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,630 | 0,00 % | XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing | RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter")... ► Artikel lesen | |
| AKESO | 10,700 | -5,31 % | Akeso, Inc.: Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab | HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global... ► Artikel lesen | |
| MEIRAGTX | 6,500 | 0,00 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| MAAT PHARMA | 7,040 | -0,56 % | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,052 | +1,76 % | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,340 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,05 | +0,22 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen |
Das Unternehmen DIAGONAL BIO AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,004 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.